Novel approaches to the treatment of primary amyloidosis

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2343-2350

  Sezer, O ^a   Niemoller, K ^a   Jakob, C ^a   Langelotz, C ^a   Eucker, J ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Amyloidosis; Heart failure; High dose chemotherapy; Immunoglobulin light chains; Monoclonal gammopathies; Nephrotic syndrome; peripheral blood stem cell transplantation; Plasma cell dyscrasia

Indexed keywords

4' IODOESORUBICIN; ALPHA INTERFERON; AMYLOID PRECURSOR PROTEIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; COLCHICINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; LIPOSOME; MELPHALAN; PREDNISONE; VINCRISTINE;

AMYLOIDOSIS; AUTOTRANSPLANTATION; CARDIOTOXICITY; CARPAL TUNNEL SYNDROME; CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; HEPATOMEGALY; HUMAN; KIDNEY AMYLOIDOSIS; MACROGLOSSIA; ORTHOSTATIC HYPERTENSION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PROGNOSIS; PROTEINURIA; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL; TARGET ORGAN;

EID: 0033814781     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2343     Document Type: Review

References (50)

1. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989
2. Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis
3. Chromosomal abnormalities in systemic amyloidosis
4. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
5. The systemic amyloidoses
6. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure
7. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component
8. SAP scintigraphy and turnover studies demonstrate regression of amyloidosis
9. Biology and therapy of immunoglobulin deposition diseases
10. The use of subcutaneous fat tissue for amyloid typing by enzyme-linked immunosorbent assay
11. Production and immuno-diagnostic applications of antihuman light chain monoclonal antibodies
12. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients
13. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients
14. Recurrence of renal amyloid and de novo membranous glomerulonephritis after transplantation
15. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement
16. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis
17. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement
18. Hepatic amyloidosis: Clinical appraisal in 77 patients
19. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy
20. Pupil abnormality in amyloidosis with autonomic neuropathy
21. Cerebrovascular involvement in systemic AA and AL amyloidosis: A clear haematogenic pattern
22. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis
23. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
24. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin
25. Treatment of AL amyloidosis with 4'-Iodo-4'-Deoxydoxorubicin: An update
26. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo
27. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine
28. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone and colchicine versus colchicine only
29. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone and melphalan, prednisone and colchicine
30. Prospective randomized trial of melphalan and prenisone versus vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of primary systemic amyloidosis
31. Effective treatment of advanced multiple myeloma refractory to alkylating agents
32. Treatment of AL amyloidosis without myeloma
33. Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival
34. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone
35. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
36. A Phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma
37. Phase I study of doxil and vinorelbine in metastatic breast cancer
38. Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first-line therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity
39. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma
40. Phase I study of liposomal daunorubicin in patients with acute leukemia
41. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon
42. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis
43. Phase II trial of high-dose dexamethasone for previously treated primary systemic amyloidosis
44. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: Survival and responses in 25 patients
45. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients
46. High treatment related mortality in cardiac amyloid patients supports the use of less intensive, non cardiotoxic PBSC collection and induction regimens
47. New therapeutic approaches in primary systemic AL amyloidosis
48. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support
49. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation
50. Allogeneic bone marrow transplantation for AL amyloidosis